ClinicalTrials.gg
CompletedNCT03294395NABOGOUpdated Aug 6, 2021

New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea

A Phase 3 interventional study of Ertapenem 1000 MG and Fosfomycin Oral Suspension in Gonorrhea, sponsored by Public Health Service of Amsterdam. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-06.

Sponsored by Public Health Service of Amsterdam · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the efficacy of three experimental antibiotics in the treatment of uncomplicated anogenital gonorrhoea. Participants will be randomized to one of four study arms and will receive either one of the three experimental antibiotics (ertapenem, fosfomycin and gentamicin) or the current standard antibiotic (ceftriaxone). Both the study team and the participant are blinded to the administered treatment. This enables the investigators to compare the eradication capacity and safety of the experimental antibiotics with the standard treatment.

*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.

Read the detailed description

Antimicrobial resistance (AMR) to extended spectrum cephalosporins (ESC) among Neisseria gonorrhoeae (Ng) is a major public health concern. With no alternative antimicrobial treatment options for gonorrhoea and only a few new drugs in the development pipeline, it is important to test existing antibiotics for their efficacy in gonorrhoea treatment. This project aims to identify new treatment modalities for uncomplicated gonorrhoea using the registered drugs ertapenem, fosfomycin and gentamicin. This trial is a double blind randomized clinical non-inferiority trial with four treatment arms. 108 participants are randomly assigned to each study arm . Participants will receive either ceftriaxone 500mg intramuscularly (IM) or ertapenem 1000mg IM or gentamicin 5mg/kg IM with a maximum of 400mg (in two doses) supplemented with an oral placebo, or receive fosfomycin 6g oral suspension supplemented with an intramuscular placebo. The bacterial eradication capacity of the study antimicrobials at the included infection site is measured 7-14 days after treatment, using an RNA-based Nucleic Acid Amplification Test (NAAT).

*Following the advise of the DSMB based on a planned interim analysis, in October 2018 one study arm (fosfomycin 6g PO) was dropped and the randomized clinical trial was continued with three treatment arms (ceftriaxone 500mg IM, ertapenem 1000mg IM and gentamicin 5mg/kg IM) and without the oral placebo.

02

Conditions studied

  • Gonorrhea

Browse trials for

Keywords

  • Antimicrobial resistance
  • Antibiotics
  • Fosfomycin
  • Ertapenem
  • Gentamicin
  • Neisseria Gonorrhoeae
03

In context

Gonorrhea

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

This study's enrollment of 346 is close to the median of 380 across 126 interventional studies indexed under Gonorrhea.

Browse Gonorrhea studies →

Lead sponsor

Public Health Service of Amsterdam is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria main study

  • 18 years or older
  • Anorectal, cervical/vaginal or urethral Ng infection, diagnosed by the following:

    • Ng-positive Gram-stained smear (intracellular Gram-negative diplococci and leukocytes) and/or
    • Positive for Ng by nucleic acid amplification test (NAAT) (Aptima Combo 2) and/or
    • Positive for Ng by culture
  • Provide samples from the included infection site for NAAT and direct culture immediately before treatment
  • Willing to abstain from anal, vaginal and oral sex until the test of cure (TOC)-visit, or use condoms during sex
  • Willing and able to return for a TOC-visit 7-14 days after treatment
  • Provide
  • Accept intramuscular injections

Exclusion criteria main study

Pre-randomisation:

  • Suspicion of a complicated Ng infection based on signs and/or symptoms indicating pelvic inflammatory disease (PID), epididymitis, prostatitis or gonococcal arthritis*
  • Another (sexually transmitted) infection or a suspicion of another infection for which systemic antimicrobial therapy is indicated
  • Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)
  • Not able to read/understand Dutch or English
  • infection if:

    • Newly diagnosed HIV infection (upon the inclusion visit) and/or
    • \<200 cells/μL (as reported by the patient)
  • Known allergy or adverse reactions to ceftriaxone, ertapenemor gentamicin
  • Known renal impairment (based on estimated using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)
  • Known liver cirrhosis (based on history)
  • Known congestive heart failure (based on history)
  • Known myasthenia gravis
  • Known hearing loss or balance disorder, confirmed by an ear-nose-throat (ENT)-doctor or for which an ENT doctor has been consulted and a diagnostic process is still in progress (based on history)
  • Concurrent use of any of the following medication:

    • systemic antibacterial antimicrobials other than nitrofurantoin or metronidazole
    • systemic drugs
    • systemic valproic acid
  • Use of any antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)
  • Previous enrollment in the study
  • Concurrent participation in other non-observational medical research*
  • Unlikely to adhere to the study protocol

Post-randomisation:

Exclusion of participants from the modified intention to treat analysis (mITT):

  • Negative result of Ng NAAT of sample collected on T0 (the day of treatment). This could be the case in the following situations:

    1. Negative NAAT in spite of positive gram stain.
    2. Positive NAAT on pre-study visit but spontaneous clearance of the infection in the time period between first test and return visit for treatment (=study inclusion visit). A novel sample for NAAT will be collected on the study inclusion visit just before administration of treatment; if these results are Ng-negative a participant will be excluded of mITT.
  • Loss to follow-up, i.e. no study visit TOC 7-14 days after treatment administration.

Exclusion from per protocol analysis (PP):

  • Exclusion of mITT
  • Use of non-study related antibiotics after inclusion and prior to TOC visit
  • Condomless sexual contact with the primary anatomical gonorrhea site involved after inclusion and prior to TOC visit
  • Other protocol violations

Inclusion criteria PK substudy (healthy volunteers):

  • 18 years or older
  • Provide informed consent

Exclusion criteria PK substudy (healthy volunteers)

Pre-randomisation:

  • Pregnancy, having a wish to become pregnant or breastfeeding (tested at inclusion visit)
  • Not able to read/understand Dutch or English
  • Known allergy or adverse reactions to ceftriaxone, ertapenem, or fosfomycin.
  • Known renal impairment (based on estimated GFR using Cockroft and Gault formula using serum creatinin measured with a point-of-care (POC) test; cut off value renal impairment eGFR ≤ 50 ml/min)
  • Known liver cirrhosis (based on history)
  • Concurrent use of any of the following medication:

    • systemic valproic acid
    • systemic metoclopramide
  • Use of any systemic antimicrobial therapy other than nitrofurantoin or metronidazole in the two weeks prior to study enrollment (based on history)
  • Concurrent participation in other non-observational medical research (apart from NABOGO RCT)
  • Unlikely to adhere to the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
346 participants (actual)

Study arms

  • Active comparator
    Ceftriaxone im

    Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)

    Drug: Ceftriaxone

  • Experimental
    Ertapenem im

    Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)

    Drug: Ertapenem 1000 MG

  • Experimental
    Fosfomycin po

    Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)

    Drug: Fosfomycin Oral Suspension

  • Experimental
    Gentamicin im

    Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)

    Drug: Gentamicin Sulfate, Injectable

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants with treatment success in each study arm for the included anatomic infection

    Proportion of participants with treatment success in each study arm using a molecular test (Nucleic acid amplification test, NAAT). Treatment succes is defined as a negative test of cure (NAAT) 7-14 days after treatment.

    Time frame: 7-14 days after treatment

Secondary outcomes

  1. Proportion of participants with treatment success in each study arm at all anatomical infection sites

    Proportion of participants with treatment success in each study arm using a molecular test (Nucleic acid amplification test, NAAT). Treatment succes is defined as a negative test of cure (NAAT) 7-28 days after treatment.

    Time frame: 7-28 days after treatment

  2. Incidence of treatment-emergent adverse events

    The incidence, type and severity of treatment-related adverse events as assessed by CTCAE v4.0 will be measured.

    Time frame: until 30 days after treatment

  3. Antimicrobial susceptibility of Ng-strains to study antibiotics

    The in vitro antimicrobial susceptibility (in MIC) of the experimental and reference treatment will be measured in all Ng strains collected at all infected anatomical sites of each participant at inclusion and in case of a positive test of cure.

    Time frame: Day 0 (before treatment) - 28 (after treatment)

  4. Blood plasma concentration of ceftriaxone, ertapenem and gentamicin in a subset of 60 NABOGO participants

    The blood plasma concentration will be measured 1 times within the first 24 hours after treatment administration. With these measurements the investigators will estimate the population pharmacokinetics of ceftriaxone, ertapenem and gentamicin.

    Time frame: within 24 hours after treatment administration

  5. Duration of symptoms after treatment

    All participants are asked to report their symptoms daily in a diary, this will be evaluated at the follow-up visit (7-14 days after treatment) and at the online evaluation questionnaire (30 days after treatment). The mean duration of all symptoms after treatment will be measured for all study antibiotics.

    Time frame: 1-30 days after treatment

  6. Clinical and demographic predictors for treatment failure

    The investigators will measure if demographic (e.g. gender, HIV status) and clinical factors (e.g. anatomical location, duration of symptoms before treatment) are associated with treatment failure (treatment failure is defined as any case in which the participant received escape medication).

    Time frame: until 7-14 days after treatment

  7. Blood plasma concentration of ceftriaxone, ertapenem and fosfomycin in 60 healthy volunteers

    Healthy volunteers will be randomly assigned to one of the three antibiotics. After administration of the antibiotic, the blood plasma concentration will be measured 4 times within the first 24 hours. With these measurements the investigators will estimate the population pharmacokinetics of ceftriaxone, ertapenem and fosfomycin.

    Time frame: 24 hours

07

Study locations

1 site
  • Public Health Service
    Amsterdam, Noord Holland 1018WT, Netherlands
08

References and documents

Publications

  • de Vries HJC, de Laat M, Jongen VW, Heijman T, Wind CM, Boyd A, de Korne-Elenbaas J, van Dam AP, Schim van der Loeff MF; NABOGO steering group. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis. 2022 May;22(5):706-717. doi: 10.1016/S1473-3099(21)00625-3. Epub 2022 Jan 19. PubMed 35065063 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Jun 2020, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2017
First posted
Sep 27, 2017
StartActual
Sep 18, 2017
Primary completionActual
Jun 5, 2020
CompletionActual
Jun 5, 2020
Last update
Aug 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03294395
Lead sponsor
Public Health Service of Amsterdam
Responsible party
Henry J.C. de Vries (Professor MD, PhD, Public Health Service of Amsterdam) — Principal investigator
First posted
Sep 27, 2017
Start date
Sep 18, 2017
Primary completion
Jun 5, 2020
Completion
Jun 5, 2020
Last update
Aug 6, 2021

Study contacts

Henry JC de Vries, PhD, MD
principal investigator · Public Health Service of Amsterdam

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ertapenem · Fosfomycin · Gentamicins

Start the discussion